Definition and epidemiology
Autoimmune disease refers to a heterogeneous group of over 80 recognized conditions unified by a common mechanism: the immune system fails to distinguish self from non-self and mounts a pathologic response against the body's own cells, tissues, or organs.
Collectively, autoimmune diseases affect an estimated 5-8% of the population worldwide, making them one of the largest disease categories after cardiovascular disease and cancer. Most show a strong female predominance (often 3:1 to 9:1), particularly during reproductive years, implicating sex hormones and X-chromosome-linked immune genes.
Classification
- Organ-specific: Hashimoto thyroiditis, Graves disease, type 1 diabetes mellitus, pernicious anemia, Addison disease, primary biliary cholangitis
- Systemic (non-organ-specific): systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome, systemic sclerosis, mixed connective tissue disease, vasculitides
ICD-10 code D84.9 is used for unspecified immune deficiency with autoimmune features, while M35.9 captures unspecified systemic involvement of connective tissue; in practice, the specific disease code (e.g., SLE = M32, rheumatoid arthritis = M05/M06) is used whenever a diagnosis is established.
- Autoimmune disease shows strong female predominance, especially during reproductive years
- HLA-DR/DQ associations are classic exam links (HLA-B27 with ankylosing spondylitis, HLA-DR3/4 with type 1 diabetes)
- Molecular mimicry explains post-infectious autoimmunity (e.g., rheumatic fever after strep pharyngitis)
- ANA is sensitive but not specific; anti-dsDNA and anti-Smith are specific for SLE
- Low C3/C4 complement suggests active immune-complex disease such as lupus nephritis
- Smoking is a major modifiable risk factor for rheumatoid arthritis and Graves disease
- Drug-induced lupus (hydralazine, procainamide, isoniazid) resolves after stopping the drug
- Treatment goal is disease control/remission, not cure, for most systemic autoimmune diseases
Etiology and risk factors
Autoimmune disease arises from an interaction between genetic susceptibility and environmental triggers that break immune tolerance.
Genetic factors
- HLA associations: HLA-DR/DQ alleles (e.g., HLA-DR3/DR4 in type 1 diabetes, HLA-DR4 in rheumatoid arthritis, HLA-B27 in ankylosing spondylitis)
- Polymorphisms in immune regulatory genes (PTPN22, CTLA4, AIRE)
- Monogenic defects (AIRE mutation causing APECED/APS-1; FOXP3 mutation causing IPEX syndrome)
- Family history and twin concordance confirm heritability, though concordance in monozygotic twins is incomplete, pointing to environmental contribution
Environmental and host triggers
- Infections (molecular mimicry): group A Streptococcus and rheumatic fever, Epstein-Barr virus and SLE/multiple sclerosis
- Smoking (strongly linked to rheumatoid arthritis and Graves disease)
- UV light exposure (triggers SLE flares)
- Drugs (hydralazine, procainamide, isoniazid causing drug-induced lupus)
- Female sex hormones (estrogen enhances B-cell survival and autoantibody production)
- Microbiome alterations and vitamin D deficiency (proposed contributors)
Pathophysiology
The core defect is a loss of self-tolerance, which normally occurs through central (thymic/bone marrow deletion of autoreactive clones) and peripheral (anergy, regulatory T cells, apoptosis) mechanisms.
Key mechanisms
- Molecular mimicry: microbial antigens resembling self-antigens activate cross-reactive T or B cells
- Epitope spreading: an initial narrow immune response broadens to target additional self-antigens over time
- Defective regulatory T cell (Treg) function: reduced suppression of autoreactive lymphocytes
- Polyclonal B-cell activation: production of multiple autoantibodies
- Bystander activation: tissue damage from infection releases self-antigens that are then targeted
Effector mechanisms of tissue damage
| Type | Example mechanism | Disease example |
|---|---|---|
| Type II hypersensitivity | Antibody against cell-surface/matrix antigen | Goodpasture syndrome, myasthenia gravis |
| Type III hypersensitivity | Immune complex deposition | SLE nephritis |
| Type IV hypersensitivity | T-cell mediated tissue injury | Type 1 diabetes, Hashimoto thyroiditis |
Chronic inflammation from these mechanisms leads to progressive tissue destruction, fibrosis, or dysfunction of the targeted organ(s).
Clinical features
Presentation varies enormously depending on which organ systems are targeted, but common threads exist across autoimmune disease.
Constitutional symptoms
- Fatigue, low-grade fever, unintentional weight change, malaise
Organ-specific clues
- Joints: symmetric polyarthritis (rheumatoid arthritis), morning stiffness
- Skin: malar rash, photosensitivity (SLE); dry skin and sclerosis (systemic sclerosis)
- Exocrine glands: dry eyes and dry mouth (Sjögren syndrome)
- Endocrine: goiter and hypothyroid symptoms (Hashimoto); tremor and weight loss (Graves)
- Neuromuscular: fatigable weakness worsening with activity (myasthenia gravis)
- Hematologic: pallor from hemolytic anemia or cytopenias
Many patients present with an overlapping, nonspecific picture (arthralgia, fatigue, rash) before a specific diagnosis crystallizes, which is why autoimmune disease often requires serial evaluation over time.
Diagnosis
Diagnosis combines clinical pattern recognition with autoantibody testing and, when needed, tissue biopsy or imaging.
Screening and confirmatory tests
- Antinuclear antibody (ANA): sensitive screening test for SLE and other connective tissue diseases, but not specific
- Disease-specific antibodies: anti-dsDNA and anti-Smith (SLE), anti-CCP and rheumatoid factor (rheumatoid arthritis), anti-TPO (Hashimoto), anti-TSH receptor (Graves), anti-acetylcholine receptor (myasthenia gravis), c-ANCA/PR3 and p-ANCA/MPO (vasculitides)
- Inflammatory markers: ESR and CRP support activity assessment but are nonspecific
- Complement levels (C3, C4): often low during active immune-complex disease such as lupus nephritis
Additional workup
- Tissue biopsy (renal, skin, salivary gland) when organ involvement needs confirmation
- Imaging (joint ultrasound/MRI, echocardiography for pericardial/valvular involvement)
- Classification criteria (e.g., ACR/EULAR criteria for SLE and rheumatoid arthritis) are used in research and to standardize diagnosis, though clinical judgment remains central
No single test diagnoses "autoimmune disease" generically; diagnosis is always disease-specific.
Differential diagnosis
Because symptoms are often nonspecific, broad differentials must be considered before attributing findings to autoimmune disease.
- Chronic infection (e.g., viral hepatitis, HIV, endocarditis) mimicking systemic inflammation
- Malignancy (lymphoma, paraneoplastic syndromes) presenting with fatigue, fever, cytopenias
- Fibromyalgia and chronic fatigue syndrome (overlap with diffuse pain/fatigue, normal serology)
- Drug-induced lupus (resolves after stopping offending drug)
- Primary hematologic disease (idiopathic cytopenias without underlying autoimmune trigger)
- Endocrinopathy from non-autoimmune causes (e.g., iodine-induced thyroid dysfunction)
A positive ANA alone is not diagnostic, as it can occur in healthy individuals and in infections, so clinical correlation is mandatory.
Management
Treatment is disease-specific but follows shared principles across major international guidelines (ACR, EULAR, WHO consensus where applicable).
General principles
- Treat to the lowest disease activity or remission achievable while minimizing drug toxicity
- Stepwise or combination immunosuppression based on severity and organ involvement
- Regular monitoring for drug toxicity and disease flares
- Vaccination status review before starting immunosuppressants (live vaccines generally contraindicated once immunosuppressed)
Pharmacologic classes
- NSAIDs and corticosteroids: rapid control of inflammation and symptoms, bridging therapy
- Conventional disease-modifying agents: methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, sulfasalazine
- Biologic agents: TNF inhibitors, rituximab (B-cell depletion), belimumab (anti-BAFF in SLE), IL-6 and IL-17 inhibitors depending on disease
- Hormone replacement: levothyroxine for autoimmune hypothyroidism; insulin for type 1 diabetes
Non-pharmacologic
- Smoking cessation (reduces flares in rheumatoid arthritis and improves overall outcomes)
- Sun protection (reduces SLE flares)
- Physical therapy and exercise to preserve function
- Multidisciplinary care (rheumatology, nephrology, endocrinology as needed)
European (EULAR) and American (ACR) guidelines broadly converge on early, targeted immunosuppression, though specific drug sequencing and biologic choice may differ by region and payer access.
Complications and prognosis
Prognosis depends heavily on the specific disease, organ involvement, and response to treatment.
Complications
- Organ damage from chronic inflammation (renal failure in lupus nephritis, joint destruction in rheumatoid arthritis)
- Increased cardiovascular risk (accelerated atherosclerosis in SLE and rheumatoid arthritis)
- Infection risk from long-term immunosuppression
- Increased risk of certain malignancies (e.g., lymphoma in Sjögren syndrome)
- Pregnancy complications (antiphospholipid syndrome, neonatal lupus from maternal antibodies)
Prognosis
- Many autoimmune diseases are chronic and relapsing-remitting rather than curable; the goal of therapy is disease control and preserved quality of life
- Early diagnosis and treatment significantly improve long-term organ-sparing outcomes
- Some organ-specific diseases (e.g., autoimmune hypothyroidism) have excellent prognosis with hormone replacement alone
- Multisystem diseases with major organ involvement (lupus nephritis, systemic sclerosis with pulmonary involvement) carry higher morbidity and mortality
"SOAP BRAIN MD" is used for SLE classification criteria (Serositis, Oral ulcers, Arthritis, Photosensitivity, Blood disorders, Renal involvement, ANA, Immunologic disorder, Neurologic disorder, Malar rash, Discoid rash) — a useful entry point into systemic autoimmune disease features generally.
Practice questions
1. A 28-year-old woman presents with a 3-month history of fatigue, joint pain, and a rash over her cheeks and nose that worsens with sun exposure. Laboratory testing reveals a positive ANA and positive anti-dsDNA antibody. Which of the following additional laboratory findings would most support active renal involvement in this patient?
2. A 45-year-old man develops joint pain, a malar-sparing rash, and positive ANA and anti-histone antibodies two months after starting a new antihypertensive medication. Anti-dsDNA is negative. Which medication is most likely responsible?
3. A 35-year-old woman presents with symmetric swelling and pain in the metacarpophalangeal and proximal interphalangeal joints bilaterally, worse in the morning and improving with activity. Serology shows positive rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Which cytokine is a key therapeutic target in this condition?
Frequently asked questions
What causes autoimmune disease?
Autoimmune disease is caused by a combination of genetic susceptibility (particularly certain HLA alleles) and environmental triggers such as infections, smoking, UV light, or certain drugs that together break immune self-tolerance. This leads autoreactive T and B cells to attack the body's own tissues. No single cause applies to all autoimmune diseases; each has its own specific risk factor profile.
What are the first symptoms of autoimmune disease?
Early symptoms are often nonspecific: fatigue, low-grade fever, joint pain or stiffness, and mild weight change. More specific clues depend on the organ targeted, such as a facial rash in lupus or dry eyes and mouth in Sjögren syndrome. Because early symptoms overlap with many other conditions, diagnosis often takes time and repeated evaluation.
How is autoimmune disease diagnosed?
Diagnosis relies on recognizing a clinical pattern plus autoantibody testing specific to the suspected disease, such as anti-dsDNA for lupus or anti-CCP for rheumatoid arthritis. Inflammatory markers (ESR, CRP) and imaging or biopsy may support the diagnosis when organ involvement needs confirmation. There is no single universal test for autoimmune disease as a category.
Is autoimmune disease curable?
Most autoimmune diseases are not curable but are manageable chronic conditions with periods of remission and flare. Treatment aims to control inflammation, prevent organ damage, and maintain quality of life rather than eliminate the disease. Some organ-specific forms, like autoimmune hypothyroidism, are easily controlled with lifelong hormone replacement.
Autoimmune disease vs allergy — what is the difference?
Autoimmune disease involves the immune system attacking the body's own tissues, while an allergy is an exaggerated immune response against a foreign, usually harmless substance like pollen or food. Autoimmune disease typically involves T and B cells and autoantibodies against self-antigens, whereas classic allergy is driven by IgE and mast cell/basophil activation against external allergens.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: D84.9
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.